NCT04910126 is a Phase 2 clinical trial of Camrelizumab in Soft Tissue Sarcoma, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT04910126?

Interventions in NCT04910126: Camrelizumab, Adriamycin.

What condition does NCT04910126 study?

NCT04910126 studies Soft Tissue Sarcoma, Neoplasms, Connective and Soft Tissue, Sarcoma Metastatic, Sarcoma,Soft Tissue.

Is NCT04910126 still recruiting?

NCT04910126 is currently status unknown. Last updated 2 June 2021.

Last reviewed 2021-06-02 · How we verify

NCT04910126

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Status unknown Phase 2 Last updated 2 June 2021

What this trial tests

Phase 2 trial testing Camrelizumab in Soft Tissue Sarcoma in 84 participants. Status unknown.

Timeline

12 November 2020

Primary endpoint
12 January 2023

12 November 2023

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	84
Start date	12 November 2020
Primary completion	12 January 2023
Estimated completion	12 November 2023
Sites	1 location across China

Drugs / interventions tested

Camrelizumab — full drug profile →
Adriamycin — full drug profile →

Conditions studied

Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →
Neoplasms, Connective and Soft Tissue — all drugs for Neoplasms, Connective and Soft Tissue →
Sarcoma Metastatic — all drugs for Sarcoma Metastatic →
Sarcoma,Soft Tissue — all drugs for Sarcoma,Soft Tissue →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 60, any sex, with Soft Tissue Sarcoma or Neoplasms, Connective and Soft Tissue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas.
Tian Z, Yao W. · · 2022 · cited 8× · PMID 36072581 · DOI 10.3389/fimmu.2022.898255

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04910126 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 2 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04910126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing